Histologically proven non-alcoholic fatty liver disease and clinically related factors in recipients after liver transplantation

Clinical Transplantation

Volumn 28, Issue 5, 2014, Pages 521-529

  Kim, Hyeyoung ^a   Lee, Kyoungbun ^a   Lee, Kwang Woong ^a   Yi, Nam Joon ^a   Lee, Hae Won ^a   Hong, Geun ^a   Choi, Youngrok ^a   You, Tae ^a   Suh, Suk Won ^a   Jang, Ja June ^a   Suh, Kyung Suk ^a  

^a Seoul National University   (South Korea)

Author keywords

Biopsy; Hepatic steatosis; Histology; Steatohepatitis; Steatosis; Transplant

Indexed keywords

ADULT; AGED; ARTICLE; DISEASE SEVERITY; FEMALE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; BIOPSY; COMPLICATION; DISEASE COURSE; EPIDEMIOLOGY; FIBROSIS; FOLLOW UP; LIVER DISEASES; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK; SOUTH KOREA; YOUNG ADULT;

ADULT; AGED; BIOPSY; DISEASE PROGRESSION; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; PREVALENCE; PROGNOSIS; RECURRENCE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84899954382     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12343     Document Type: Article

References (52)

1. Lee JY, Kim KM, Lee SG et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007: 47: 239.
2. Burke A, Lucey MR. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation. Am J Transplant 2004: 4: 686.
3. Hubscher SG. What is the long-term outcome of the liver allograft? J Hepatol 2011: 55: 702.
4. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009: 15: 1662.
5. Seo S, Maganti K, Khehra M et al. De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 2007: 13: 844.
6. Ekong UD. The long-term liver graft and protocol biopsy: do we want to look? What will we find? Curr Opin Organ Transplant 2011: 16: 505.
7. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011: 53: 810.
8. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007: 47: 598.
9. Kleiner DE, Brunt EM, van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005: 41: 1313.
10. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012: 32: 3.
11. Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2005: 2012: 55.
12. Oh SW. Obesity and metabolic syndrome in Korea. Diabetes Metab J 2011: 35: 561.
13. Kim DM, Ahn CW, Nam SY. Prevalence of obesity in Korea. Obes Rev 2005: 6: 117.
14. Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001: 285: 2486.
15. Fan JG, Zhu J, Li XJ et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005: 43: 508.
16. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006: 43: S99.
17. Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 2013: 73: 1.
18. Wong VW. Nonalcoholic fatty liver disease in Asia: a story of growth. J Gastroenterol Hepatol 2013: 28: 18.
19. Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010: 53: 199.
20. Lucey MR, Terrault N, Ojo L et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013: 19: 3.
21. Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl 2006: 12: 523.
22. Jonas MM, Krawczuk LE, Kim HB, Lillehei C, Perez-Atayde A. Rapid recurrence of nonalcoholic fatty liver disease after transplantation in a child with hypopituitarism and hepatopulmonary syndrome. Liver Transpl 2005: 11: 108.
23. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010: 16: 431.
24. Zahmatkeshan M, Geramizadeh B, Eshraghian A et al. De novo fatty liver due to vascular complications after liver transplantation. Transplant Proc 2011: 43: 615.
25. Dumortier J, Giostra E, Belbouab S et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil." Am J Gastroenterol 2010: 105: 613.
26. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002: 346: 1221.
27. Wierzbicki AS, Oben J. Nonalcoholic fatty liver disease and lipids. Curr Opin Lipidol 2012: 23: 345.
28. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006: 40(Suppl 1): S5.
29. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011: 34: 274.
30. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002: 122: 1649.
31. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 1820: 2010: 51.
32. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005: 42: 132.
33. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009: 51: 371.
34. Rahimi RS, Landaverde C. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Nutr Clin Pract 2013: 28: 40.
35. Wong VW, Wong GL, Choi PC et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010: 59: 969.
36. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004: 40: 1387.
37. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003: 37: 917.
38. Welshi JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010. J Pediatr 2013: 162: 496.
39. Bhatia LS, Curzen NP, Byrne CD. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol 2012: 27: 420.
40. Targher G, Bellis A, Fornengo P et al. Prevention and treatment of nonalcoholic fatty liver disease. Dig Liver Dis 2010: 42: 331.
41. Targher G, Valbusa F, Bonapace S et al. Non-alcoholic Fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS ONE 2013: 8: e57183.
42. Dunn W, Xu R, Wingard DL et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008: 103: 2263.
43. Kasturiratne A, Weerasinghe S, Dassanayake AS et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. J Gastroenterol Hepatol 2013: 28: 142.
44. Koehler E, Watt K, Charlton M. Fatty liver and liver transplantation. Clin Liver Dis 2009: 13: 621.
45. Kim D, Choi SY, Park EH et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012: 56: 605.
46. Kawada N, Imanaka K, Kawaguchi T et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009: 44: 1190.
47. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005: 129: 113.
48. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P. The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009: 58: 1538.
49. Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with non-alcoholic fatty liver disease (NAFLD), metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 2012: 62: 352.
50. Sprinzl MF, Weinmann A, Lohse N et al. Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. Transpl Int 2013: 26: 67.
51. Dureja P, Mellinger J, Agni R et al. NAFLD recurrence in liver transplant recipients. Transplantation 2011: 91: 684.
52. Margariti A, Deutsch M, Manolakopoulos S, Tiniakos D, Papatheodoridis GV. The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol 2013: 47: 280.